AstriVax Therapeutics is a European based, biopharmaceutical company, founded in 2022, that is pioneering immune interventions to treat chronic disease. The company has two prototype prophylactic assets in clinical phase and is developing its therapeutic assets to treat chronic hepatitis B (HBV) and clear high-risk human papilloma virus infection (HPV). AstriVax has a novel DNA-launched viral vector immunotherapy platform, Launch-iT, that provides company the potential to develop best-in-class immunotherapy treatments.